Literature DB >> 9600590

Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease.

K Wakabayashi1, A Kakita, S Hayashi, K Okuizumi, O Onodera, H Tanaka, A Ishikawa, S Tsuji, H Takahashi.   

Abstract

To elucidate whether the apolipoprotein E epsilon4 allele (APOE4) affects cortical neuropathology in Parkinson's disease (PD), we determined APOE genotypes and quantified the densities of cortical Lewy bodies (LBs), amyloid plaques and neurofibrillary tangles in 22 autopsy-proven PD cases (12 with dementia; 10 without dementia) that were not accompanied by Alzheimer's disease. The APOE4 frequency in the demented patient group was 0.21, which was significantly higher than that in Japanese controls (P < 0.04). LB densities in demented PD patients were significantly higher than those in non-demented PD patients, despite the shorter disease duration in the former. Moreover, plaque density in the temporal cortex and LB density in the cingulate cortex were significantly higher in the group with APOE4 than in that without the allele. There was no difference in tangle density between these two groups. These results suggest that APOE4 may influence the increase in the number of cortical LBs and amyloid plaques in PD. It is possible that when PD occurs in individuals with APOE4, concomitantly evolving cortical LB pathology in a proportion of cases results in limbic (transitional) or neocortical-type LB disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600590     DOI: 10.1007/s004010050824

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  8 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

2.  Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease.

Authors:  D W Tsuang; R K Wilson; O L Lopez; E K Luedecking-Zimmer; J B Leverenz; S T DeKosky; M I Kamboh; R L Hamilton
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

Review 3.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

Review 4.  Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.

Authors:  David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2013-07-31       Impact factor: 34.870

5.  Immunolocalization of an amino-terminal fragment of apolipoprotein E in the Pick's disease brain.

Authors:  Troy T Rohn; Ryan J Day; Lindsey W Catlin; Raquel J Brown; Alexander J Rajic; Wayne W Poon
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 6.  Cholesterol Metabolism in the Brain and Its Association with Parkinson's Disease.

Authors:  Uram Jin; Soo Jin Park; Sang Myun Park
Journal:  Exp Neurobiol       Date:  2019-10-31       Impact factor: 3.261

7.  Neuronal ApoE Regulates the Cell-to-Cell Transmission of α-Synuclein.

Authors:  Seo-Jun Kang; Soo-Jeong Kim; Hye Rin Noh; Beom Jin Kim; Jae-Bong Kim; Uram Jin; Sun Ah Park; Sang Myun Park
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

8.  Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Authors:  Cristina Nombela; James B Rowe; Sophie E Winder-Rhodes; Adam Hampshire; Adrian M Owen; David P Breen; Gordon W Duncan; Tien K Khoo; Alison J Yarnall; Michael J Firbank; Patrick F Chinnery; Trevor W Robbins; John T O'Brien; David J Brooks; David J Burn; Roger A Barker
Journal:  Brain       Date:  2014-07-30       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.